Pharmacokinetics and Pharmacodynamics of PEGylated IFN-β 1a Following Subcutaneous Administration in Monkeys

By Mager Donald E.   Neuteboom Berend   Jusko William J.  

Pharmaceutical Research, Vol. 22, Iss. 1, 2005-01 ,pp. : 58-61

Springer Publishing Company

Access to resources Recommend Favorite

IFN- treatment cost driver in relapsing-remitting MS

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 458, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

IFN- treatment cost driver in relapsing-remitting MS

By  

Inpharma, Vol. 1, Iss. 1448, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

IFN-β, IFN-γ, and TNF-α decrease erythrophagocytosis by human monocytes independent of SIRP-α or SHP-1 expression

By de Almeida Ana Carolina  

Immunopharmacology and Immunotoxicology, Vol. 34, Iss. 6, 2012-12 ,pp. : 1054-1059

Informa Healthcare

Access to resources Recommend Favorite

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-&bgr;-1b treatment in relapsing remitting MS

By Goertsches Robert H   Hecker Michael   Koczan Dirk   Serrano-Fernandez Pablo   Moeller Steffen   Thiesen Hans-Juergen   Zettl Uwe K  

Pharmacogenomics, Vol. 11, Iss. 2, 2010-02 ,pp. : 147-161

Future Medicine

Access to resources Recommend Favorite